MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/ajco.13395

Медицинская библиотека · Asia-Pacific journal of clinical oncology · 2020

Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.

Okamura Misato, Fujita Kohei, Yamamoto Yuki, Kanai Osamu, Nakatani Koichi, Horimoto Kanna, Hashimoto Masayuki, Sawai Satoru, Shimosato Maiko, Yoshida Kazuya, Mio Tadashi

СтатьяПеревод в очереди

Аннотация

BACKGROUND

Over the past two decades, antiresorptive agent-related osteonecrosis of the jaw (ARONJ) has become a growing concern. We examined the incidence of ARONJ and identified its risk factors in lung cancer patients in the real-world clinical setting. To our knowledge, we are the first to do so.

PATIENTS AND

METHODS

We retrospectively analyzed lung cancer patients with bone metastases who had received anti-resorptive agents (zoledronate or denosumab) at the National Hospital Organization Kyoto Medical Center from October 2012 to September 2018. All ARONJ cases were diagnosed by the dentists according to the established diagnostic criteria.

RESULTS

A total of 171 patients were reviewed, 13 (7.6%) of whom experienced ARONJ. Among the 13 patients, six (46.2%), four (30.8%) and three (23.1%) had adenocarcinoma, squamous carcinoma and not otherwise specified, respectively. ARONJ was stage 2 in three (23.1%) patients and stage 3 in 10 (76.9%). More cycles of antiresorptive agents (odds ratio [OR] = 11.54; 95% confidence interval [CI], 2.47-53.99; P < 0.01), use of immune checkpoint inhibitors (ICIs; OR = 5.05; 95% CI, 1.56-16.37; P < 0.01) and longer survival duration (≥2 years; OR = 12.16; 95% CI, 3.17-46.65; P < 0.01) were independently associated with ARONJ in a multivariate analysis.

CONCLUSIONS

The incidence of ARONJ was relatively high in lung cancer patients with bone metastases. When using antiresorptive agents, oncologists should closely monitor patients for ARONJ during the course of treatment and regularly consult with dentists, especially in patients receiving ICIs.

Для цитирования: Okamura Misato, Fujita Kohei, Yamamoto Yuki, Kanai Osamu, Nakatani Koichi, Horimoto Kanna, Hashimoto Masayuki, Sawai Satoru, Shimosato Maiko, Yoshida Kazuya, Mio Tadashi. Single-center analysis of antiresorptive agent-related osteonecrosis of the jaw in lung cancer patients.. Asia-Pacific journal of clinical oncology. 2020. DOI: 10.1111/ajco.13395.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.